Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke.
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke.